# Ubamatamab

Source: https://onco.cc/drugs/ubamatamab/  
OnCo record `ubamatamab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ubamatamab is a monoclonal antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for ovarian cancer, endometrial cancer.

## Summary

Ubamatamab is listed on ClinicalTrials.gov as an intervention in 3 registered phase 2 trials sponsored by Regeneron Pharmaceuticals, in ovarian cancer, endometrial cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: REGN4018
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Ubamatamab: https://clinicaltrials.gov/search?intr=Ubamatamab

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- trials: [A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata](https://onco.cc/trials/nct04590326/), [A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07154290/), [Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer](https://onco.cc/trials/nct06787612/), [Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent](https://onco.cc/trials/nct03564340/)

---
JSON: https://onco.cc/api/v1/entities/ubamatamab.json